Ultragenyx Pharmaceutical (RARE)
Develops and commercializes therapies for serious rare and ultra-rare genetic diseases.
$15.68
After hours+0.07 (+0.44%)
At close$15.61(+6.55%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 109.00% | 107.46M shares | |
|---|---|---|---|
| 329 holders · as of Jun 30, 2026 | |||
| Insiders | 4.22% | 4.16M shares | |
| 16 holders · as of Sep 15, 2026 | |||
| Adds to | 113.22% | ||
98.59M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 113.22%; nothing is left for Other.
13F, as of Jun 30, 2026
329 holders · 107.46M shares · 63 new positions · 180 increased · 100 reduced · 43 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.65M | 10.81% | +3.35M | Aug 7, 2026 |
| RTW Investments, LP | 7.80M | 7.91% | +4.15M | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 6.79M | 6.89% | +1.40M | Aug 13, 2026 |
| AQR Capital Management LLC | 6.56M | 6.65% | +1.98M | Aug 14, 2026 |
| State Street Corp | 6.16M | 6.25% | +1.14M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 4.30M | 4.36% | +106.7K | Aug 13, 2026 |
| Two Sigma Investments, LP | 3.62M | 3.67% | +1.42M | Aug 14, 2026 |
| Sands Capital Management, LLC | 3.16M | 3.20% | −56.2K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 7.90% | 7.80M | 13G | Aug 14, 2026 |
| AQR Capital Management, LLC | 6.66% | 6.56M | 13G | Aug 13, 2026 |
| State Street Corporation | 6.30% | 6.16M | 13G | Aug 7, 2026 |
| Vanguard Portfolio Management | 5.50% | 5.41M | 13G | Apr 29, 2026 |
| Vanguard Capital Management | 5.13% | 5.06M | 13G | Jul 31, 2026 |
| BlackRock, Inc. | 5.10% | 4.82M | 13G | Apr 24, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 15, 2026 | Theodore Alan Huizengaofficer: SVP, Chief Accounting Officer | Sale | 1,283 | $13.57 | 67,863 |
| Sep 3, 2026 | Theodore Alan Huizengaofficer: SVP, Chief Accounting Officer | Sale | 161 | $13.99 | 69,146 |
| Aug 3, 2026 | Howard Hornofficer: Chief Financial Officer | Sale | 4,696 | $24.92 | 96,295 |
| Aug 3, 2026 | Karah Herdman Parschauerofficer: EVP and Chief Legal Officer | Sale | 1,900 | $24.92 | 92,562 |
| Jul 1, 2026 | Howard Hornofficer: Chief Financial Officer | Sale | 4,698 | $33.13 | 100,991 |
| Jun 15, 2026 | Karah Herdman Parschauerofficer: EVP and Chief Legal Officer | Sale | 1,899 | $24.62 | 94,462 |
| Jun 15, 2026 | Corazon (Corsee) D. Sandersdirector | Sale | 2,000 | $25.05 | 21,095 |
| Jun 1, 2026 | Howard Hornofficer: Chief Financial Officer | Sale | 4,653 | $23.77 | 105,689 |
| May 18, 2026 | Shehnaaz Sulimandirector | Sale | 5,740 | $25.12 | 27,951 |
| May 5, 2026 | Eric Crombezofficer: EVP and Chief Medical Officer | Sale | 344 | $24.96 | 111,189 |
House and Senate disclosures
Not reported.